Managing reactivation of multiple sclerosis during treatment with natalizumab
Multiple Sclerosis Journal · 2026
DOI: 10.1177/13524585251398682 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal, 2026. Verfasst von Nathaniel Lizak und 36 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Departmen…. Hauptthemen laut MEDLINE: Natalizumab, Immunologic Factors, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council, Multiple Sclerosis Australia.
Abstract (Originalsprache)
Background
Following natalizumab failure, it is unknown whether switching to alternative high-efficacy therapies offers superior effectiveness over continuing natalizumab.
Objective
To compare different treatment strategies following natalizumab failure.
Methods
Patients suffering a relapse during natalizumab treatment with adequate follow-up were identified from the MSBase registry. Following natalizumab failure, natalizumab continuation was compared to switching to anti-CD20 therapies/alemtuzumab/lower-efficacy therapies and treatment discontinuation. The primary outcome was the risk of further relapses. Secondary outcomes included risk of subsequent magnetic resonance imaging (MRI) activity, confirmed disability worsening and disease-activity-free survival. Multivariable proportional hazards models compared outcomes during time-varying therapy exposures. Four sensitivity analyses were conducted with varied inclusion criteria and treatment failure definitions.
Results
Of 1553 patients experiencing a relapse during natalizumab treatment, 1037 met the inclusion criteria. Following natalizumab failure, switch to anti-CD20 therapy was associated with a lower relapse risk (hazard ratio (HR) = 0.48, 95% confidence interval (CI) = 0.27–0.84) compared to continuing natalizumab; no differences were observed in MRI or disability outcomes. Treatment de-escalation or cessation was associated with increased relapse risk (HR = 1.46, 95% CI = 1.15–1.85; HR = 2.08, 95% CI = 1.22–3.55, respectively). We did not find evidence of a difference for switching to alemtuzumab. Sensitivity analyses replicated primary findings.
Conclusion
This exploratory study indicates that switching to anti-CD20 therapies following natalizumab failure is associated with a >50% reduction in relapse risk. No differences were seen in secondary outcomes, despite consistent trends. Clinicians may consider anti-CD20 therapies following natalizumab failure, noting further research is needed to confirm differences in MRI and disability outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia.
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University, Prague, Czech Republic; General University Hospital, Prague, Czech Republic.
- Department of Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain.
- Department of Neurology, The Alfred Hospital, Melbourne, VIC, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.
- Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW, Australia; Hunter New England Health, John Hunter Hospital, Newcastle, NSW, Australia.
- Department of Neurosciences, Box Hill Hospital, Melbourne, VIC, Australia; Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia.
ORCID-Profile: Nathaniel Lizak, Dana Horáková, Sara Eichau, Anneke van der Walt, Helmut Butzkueven, Pierre Duquette, Francesco Patti, Eduardo Aguera-Morales, Jens Kuhle, Nevin John, Maria Pia Amato, Riadh Gouider, Izanne Roos, Tomas Kalincik
Förderung
- National Health and Medical Research Council
- Multiple Sclerosis Australia
Zitieren
APA
Lizak, N., Sharmin, S., Horáková, D., Havrdova, E. K., Eichau, S., van der Walt, A., Butzkueven, H., Lechner-Scott, J., Buzzard, K., Skibina, O., Gerlach, O., Prat, A., Girard, M., Duquette, P., Alroughani, R., Patti, F., Grand'Maison, F., Sá, M. J., Aguera-Morales, E., …, & Kalincik, T. (2026). Managing reactivation of multiple sclerosis during treatment with natalizumab. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585251398682
Vancouver
Lizak N, Sharmin S, Horáková D, Havrdova EK, Eichau S, van der Walt A, et al. Managing reactivation of multiple sclerosis during treatment with natalizumab. Multiple Sclerosis Journal. 2026. doi:10.1177/13524585251398682
BibTeX
@article{Lizak2026,
author = {Lizak, Nathaniel and Sharmin, Sifat and Horáková, Dana and Havrdova, Eva Kubala and Eichau, Sara and van der Walt, Anneke and Butzkueven, Helmut and Lechner-Scott, Jeannette and Buzzard, Katherine and Skibina, Olga and Gerlach, Oliver and Prat, Alexandre and Girard, Marc and Duquette, Pierre and Alroughani, Raed and Patti, Francesco and Grand'Maison, Francois and Sá, Maria José and Aguera-Morales, Eduardo and Hodgkinson, Suzanne and Grammond, Pierre and Kuhle, Jens and Yamout, Bassem and Khoury, Samia J and Ozakbas, Serkan and Csepany, Tunde and John, Nevin and Laureys, Guy and Terzi, Murat and Amato, Maria Pia and Boz, Cavit and Al-Asmi, Abdullah and Cartechini, Elisabetta and Gouider, Riadh and Mrabet, Saloua and Roos, Izanne and Kalincik, Tomas},
title = {Managing reactivation of multiple sclerosis during treatment with natalizumab},
journal = {Multiple Sclerosis Journal},
year = {2026},
doi = {10.1177/13524585251398682}
}
EUVIMED